KMC Dermatology Leads Kansas with Innovative GentleCure™ Skin Cancer Treatment

KMC Dermatology Introduces GentleCure™ in Kansas

In a groundbreaking development for skin cancer treatment in Kansas, KMC Dermatology has become the first practice in the state to offer the non-surgical GentleCure™ treatment option, provided by the industry leader, SkinCure Oncology. This innovative treatment utilizes Image-Guided Superficial Radiation Therapy (IGSRT), which has demonstrated impressive success rates for nonmelanoma skin cancer, a condition afflicting over 26,000 individuals in Kansas this year.

What is GentleCure™?

GentleCure™ is a minimally invasive treatment designed specifically for nonmelanoma skin cancers, including basal and squamous cell carcinomas. Using ultrasound imaging, doctors can precisely direct low-level x-rays towards the cancerous cells on the skin, effectively eliminating them while sparing the surrounding healthy tissue. According to studies, this method boasts a remarkable cure rate of over 99% at six years post-treatment, making it a highly effective alternative to traditional methods such as Mohs surgery.

Dr. Joseph Gadzia of KMC Dermatology emphasized the significance of this development, stating, "More than 26,000 individuals in Kansas are expected to be diagnosed with nonmelanoma skin cancer this year. We know that sun exposure is the main cause of this type of cancer but there are other factors as well. For those who have been diagnosed, we now offer a nonsurgical treatment option which achieves close to the same success rate as Mohs surgery but without the complications of surgery, such as scarring and bleeding."

The Importance of Access to Treatment

At the launch event, Dr. Gadzia, along with other local officials and health professionals, shed light on the importance of providing effective treatment options in Kansas. The Kansas Governor Laura Kelly has even proclaimed June 8 to 14 as "Kansas Nonmelanoma Skin Cancer Awareness Week," spotlighting the urgency of addressing this prevalent health issue.

During the event, Kerwin Brandt, CEO of SkinCure Oncology, expressed excitement about this partnership, stating, "We are delighted to team up with KMC Dermatology to offer this highly effective, noninvasive treatment option for patients. It’s crucial for patients across the state to have access to non-surgical choices when dealing with nonmelanoma skin cancers."

Community Impact and Future Prospects

The introduction of GentleCure™ not only enhances the treatment landscape for skin cancer patients but also contributes to community awareness and education. Given that nonmelanoma skin cancer is the most common form of skin cancer, initiatives like this can significantly impact early detection and treatment acceptance.

As highlighted in recent studies, over 100,000 patients in the United States have benefited from Image-Guided SRT. This form of treatment is gaining recognition as a viable alternative to more invasive options, underlining its importance in modern dermatological practices.

Patients and healthcare professionals alike are optimistic that the introduction of GentleCure™ will help reduce the number of untreated cases and encourage preventative measures against skin cancer.

Conclusion

KMC Dermatology's role in pioneering GentleCure™ in Kansas marks a significant advancement in nonmelanoma skin cancer treatment options. With a proven track record and the backing of community leaders, this innovative treatment not only promises to enhance patient care but also fosters a deeper understanding of skin cancer prevention and treatment within the Kansas community. For those in need, KMC Dermatology now stands as a beacon of hope and healing, leading the state into a new era of skin cancer treatment.